14,15-dihydroxy-eicosa-5(Z)-enoic acid selectively inhibits 14,15-epoxyeicosatrienoic acid-induced relaxations in bovine coronary arteries

Journal of Pharmacology and Experimental Therapeutics

Volumn 336, Issue 1, 2011, Pages 47-55

  Bukhari, Ishfaq A ^a   Gauthier, Kathryn M ^a   Jagadeesh, Setti G ^b   Sangras, Bhavani ^b   Falck, J R ^b   Campbell, William B ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

11,12 EPOXY 5,8,14 ICOSATRIENOIC ACID; 12 (3 ADAMANTAN 1 YL UREIDO)DODECANOIC ACID; 14,15 DIHYDROXY EICOSA 5(Z) ENOIC ACID; 14,15 EPIOXYEICOSA 5(Z) ENOIC ACID; 14,15 EPOXY 5,8,11 ICOSATRIENOIC ACID; 5,6 EPOXY 8,11,14 ICOSATRIENOIC ACID; 8,9 EPOXYICOSATRIENOIC ACID; ARACHIDIC ACID; EPOXIDE HYDROLASE; LAURIC ACID; SOLUBLE EPOXIDE HYDROLASE; UNCLASSIFIED DRUG; VASODILATOR AGENT;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY; COW; ENDOTHELIUM; ENZYME METABOLISM; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; VASCULAR SMOOTH MUSCLE; VASODILATATION;

8,11,14-EICOSATRIENOIC ACID; ANIMALS; CATTLE; CORONARY VESSELS; DOSE-RESPONSE RELATIONSHIP, DRUG; VASODILATION;

EID: 78650777434     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.110.169797     Document Type: Article

References (36)

1. Ai D, Fu Y, Guo D, Tanaka H, Wang N, Tang C, Hammock BD, Shyy JY, and Zhu Y (2007) Angiotensin II up-regulates soluble epoxide hydrolase in vascular endothelium in vitro and in vivo. Proc Natl Acad Sci USA 104:9018-9023.
2. Campbell WB and Falck JR (2007) Arachidonic acid metabolites as endothelium-derived hyperpolarizing factors. Hypertension 49:590-596.
3. Ca channels. Am J Physiol Heart Circ Physiol 282:H1656-H1664.
4. Campbell WB, Gebremedhin D, Pratt PF, and Harder DR (1996) Identification of epoxyeicosatrienoic acids as endothelium-derived hyperpolarizing factors. Circ Res 78:415-423.
5. Carroll MA, Balazy M, Margiotta P, Falck JR, and McGiff JC (1993) Renal vasodilator activity of 5,6-epoxyeicosatrienoic acid depends upon conversion by cyclooxygenase and release of prostaglandins. J Biol Chem 268:12260-12266.
6. Carroll MA, Schwartzman M, Capdevila J, Falck JR, and McGiff JC (1987) Vasoactivity of arachidonic acid epoxides. Eur J Pharmacol 138:281-283.
7. 125Iodo-14,15-epoxyeicosa-5(Z)-enoic acid: a high-affinity radioligand used to characterize the epoxyeicosatrienoic acid antagonist binding site. J Pharmacol Exp Ther 331:1137-1145.
8. Falck JR, Krishna UM, Reddy YK, Kumar PS, Reddy KM, Hittner SB, Deeter C, Sharma KK, Gauthier KM, and Campbell WB (2003) Comparison of vasodilatory properties of 14,15-EET analogs: structural requirements for dilation. Am J Physiol Heart Circ Physiol 284:H337-H349.
9. Falck JR, Yadagiri P, and Capdevila J (1990) Synthesis of epoxyeicosatrienoic acids and heteroatom analogs. Methods Enzymol 187:357-364.
10. Fang X, Kaduce TL, Weintraub NL, Harmon S, Teesch LM, Morisseau C, Thompson DA, Hammock BD, and Spector AA (2001) Pathways of epoxyeicosatrienoic acid metabolism in endothelial cells. Implications for the vascular effects of soluble epoxide hydrolase inhibition. J Biol Chem 276:14867-14874.
11. Fang X, Kaduce TL, Weintraub NL, VanRollins M, and Spector AA (1996) Functional implications of a newly characterized pathway of 11,12- epoxyeicosatrienoic acid metabolism in arterial smooth muscle. Circ Res 79:784-793.
12. Fisslthaler B, Popp R, Kiss L, Potente M, Harder DR, Fleming I, and Busse R (1999) Cytochrome P450 2C is an EDHF synthase in coronary arteries. Nature 401:493-497. (Pubitemid 29470209)
13. Fretland AJ and Omiecinski CJ (2000) Epoxide hydrolases: biochemistry and molecular biology. Chemico-Biological Interactions 129:41-59.
14. Gauthier KM, Deeter C, Krishna UM, Reddy YK, Bondlela M, Falck JR, and Campbell WB (2002a) 14,15-Epoxyeicosa-5(Z)-enoic acid: a selective epoxyeicosatrienoic acid antagonist that inhibits endothelium-dependent hyperpolarization and relaxation in coronary arteries. Circ Res 90:1028-1036.
15. Gauthier KM, Jagadeesh SG, Falck JR, and Campbell WB (2003) 14,15-epoxyeicosa-5(Z)-enoic-mSI: a 14,15- and 5,6-EET antagonist in bovine coronary arteries. Hypertension 42:555-561.
16. Ca channel gene. J Physiol 545:829-836.
17. Gross GJ, Gauthier KM, Moore J, Falck JR, Hammock BD, Campbell WB, and Nithipatikom K (2008) Effects of the selective EET antagonist, 14,15-EEZE, on cardioprotection produced by exogenous or endogenous EETs in the canine heart. Am J Physiol Heart Circ Physiol 294:H2838-H2844.
18. Imig JD and Hammock BD (2009) Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases. Nat Rev Drug Discov 8:794-805.
19. Imig JD, Zhao X, Capdevila JH, Morisseau C, and Hammock BD (2002) Soluble epoxide hydrolase inhibition lowers arterial blood pressure in angiotensin II hypertension. Hypertension 39:690-694.
20. Larsen BT, Campbell WB, and Gutterman DD (2007) Beyond vasodilatation: non-vasomotor roles of epoxyeicosatrienoic acids in the cardiovascular system. Trends Pharmacol Sci 28:32-38.
21. Li PL and Campbell WB (1997) Epoxyeicosatrienoic acids activate K+ channels in coronary smooth muscle through a guanine nucleotide binding protein. Circ Res 80:877-884.
22. Morisseau C, Goodrow MH, Dowdy D, Zheng J, Greene JF, Sanborn JR, and Hammock BD (1999) Potent urea and carbamate inhibitors of soluble epoxide hydrolases. Proc Natl Acad Sci USA 96:8849-8854.
23. Nithipatikom K, Grall AJ, Holmes BB, Harder DR, Falck JR, and Campbell WB (2001) Liquid chromatographic-electrospray ionization-mass spectrometric analysis of cytochrome P450 metabolites of arachidonic acid. Anal Biochem 298:327-336.
24. Node K, Huo Y, Ruan X, Yang B, Spiecker M, Ley K, Zeldin DC, and Liao JK (1999) Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Science 285:1276-1279.
25. Oliw EH (1984) Metabolism of 5(6)oxidoeicosatrienoic acid by ram seminal vesicles. Formation of two stereoisomers of 5-hydroxyprostaglandin I1. J Biol Chem 259:2716-2721.
26. Oltman CL, Weintraub NL, VanRollins M, and Dellsperger KC (1998) Epoxyeicosatrienoic acids and dihydroxyeicosatrienoic acids are potent vasodilators in the canine coronary microcirculation. Circ Res 83:932-939.
27. Rosolowsky M and Campbell WB (1993) Role of PGI2 and epoxyeicosatrienoic acidsin relaxation of bovine coronary arteries to arachidonic acid. Am J Physiol 264:H327-H335.
28. Rosolowsky M and Campbell WB (1996) Synthesis of hydroxyeicosatetraenoic (HETEs) and epoxyeicosatrienoic acids (EETs) by cultured bovine coronary artery endothelial cells. Biochim Biophys Acta 1299:267-277.
29. Sinal CJ, Miyata M, Tohkin M, Nagata K, Bend JR, and Gonzalez FJ (2000) Targeted disruption of soluble epoxide hydrolase reveals a role in blood pressure regulation. J Biol Chem 275:40504-40510.
30. Spector AA and Norris AW (2007) Action of epoxyeicosatrienoic acids on cellular function. Am J Physiol Cell Physiol 292:C996-C1012.
31. VanderNoot VA and VanRollins M (2002) Capillary electrophoresis of cytochrome P-450 epoxygenase metabolites of arachidonic acid. 1. Resolution of regioisomers. Anal Chem 74:5859-5865. (Pubitemid 35364844)
32. Weintraub NL, Fang X, Kaduce TL, VanRollins M, Chatterjee P, and Spector AA (1997) Potentiation of endothelium-dependent relaxation by epoxyeicosatrienoic acids. Circ Res 81:258-267.
33. Wong PY, Lin KT, Yan YT, Ahern D, Iles J, Shen SY, Bhatt RK, and Falck JR (1993) 14(R),15(S)-Epoxyeicosatrienoic acid (14(R),15(S)-EET) receptor in guinea pig mononuclear cell membranes. J Lipid Mediat 6:199-208.
34. Yang W, Gauthier KM, Reddy LM, Sangras B, Sharma KK, Nithipatikom K, Falck JR, and Campbell WB (2005) Stable 5,6-epoxyeicosatrienoic acid analog relaxes coronary arteries through potassium channel activation. Hypertension 45:681-686.
35. Yang W, Holmes BB, Gopal VR, Kishore RV, Sangras B, Yi XY, Falck JR, and Campbell WB (2007) Characterization of 14,15-epoxyeicosatrienoyl-sulfonamides as 14,15-epoxyeicosatrienoic acid agonists: use for studies of metabolism and ligand binding. J Pharmacol Exp Ther 321:1023-1031.
36. Yang W, Tuniki VR, Anjaiah S, Falck JR, Hillard CJ, and Campbell WB (2008) Characterization of epoxyeicosatrienoic acid binding site in U937 membranes using a novel radiolabeled agonist, 20-125i-14,15-epoxyeicosa-8(Z)- enoic acid. J Pharmacol Exp Ther 324:1019-1027.